GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Astria Therapeutics Inc (NAS:ATXS) » Definitions » Interest Coverage

Astria Therapeutics (Astria Therapeutics) Interest Coverage : No Debt (1) (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Astria Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Astria Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-19.00 Mil. Astria Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. Astria Therapeutics has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Astria Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Astria Therapeutics's Interest Coverage or its related term are showing as below:


ATXS's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 125.655
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Astria Therapeutics Interest Coverage Historical Data

The historical data trend for Astria Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Astria Therapeutics Interest Coverage Chart

Astria Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A No Debt N/A No Debt

Astria Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A No Debt No Debt

Competitive Comparison of Astria Therapeutics's Interest Coverage

For the Biotechnology subindustry, Astria Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astria Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Astria Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Astria Therapeutics's Interest Coverage falls into.



Astria Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Astria Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Astria Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-67.83 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Astria Therapeutics had no debt (1).

Astria Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Astria Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-19.00 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Astria Therapeutics had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Astria Therapeutics  (NAS:ATXS) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Astria Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Astria Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Astria Therapeutics (Astria Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
75 State Street, Suite 1400, Boston, MA, USA, 02109
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
Executives
Perceptive Life Sciences Master Fund Ltd director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Andrea Matthews officer: Chief Business Officer C/O ASTRIA THERAPEUTICS, INC., 75 STATE STREET, SUITE 1400, BOSTON MA 02109
Christopher Morabito officer: Chief Medical Officer C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Andrew Komjathy officer: Chief Commercial Officer CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B14202, CAMBRIDGE MA 02139
Andrew John Nichols officer: Chief Scientific Officer C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG 1400E, CAMBRIDGE MA 02139
Perceptive Xontogeny Venture Fund, Lp director, 10 percent owner C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Jonathan Violin director 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Fred Callori director 100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Xontogeny, Llc director, 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc director, 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joanne T. Beck director C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ, BLD. 1400E, SUITE B14202, CAMBRIDGE MA 02139
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Hugh M Cole director C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Benjamin Harshbarger officer: Secretary and General Counsel ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142